Document:

<PAGE>

                                                                    Exhibit 10.2

                              SUBLICENSE AGREEMENT

This Sublicense Agreement (the "Agreement") is made by and between Star
Scientific, Inc. (hereinafter "SSI") and Star Tobacco & Pharmaceuticals, Inc.
(hereinafter "STPI"). SSI and STPI individually and collectively are hereinafter
referred to as "Party" or "Parties," as the case may be.

1. CONSIDERATION AND EFFECTIVE DATE

      1.1 The effective date of this Agreement shall be as of March 16, 2001.

      1.2 WHEREAS Regent Court Technologies ("RCT"), a general partnership of
which Jonnie K. Williams ("Williams"), of Manakin-Sabot, Virginia, and Francis
O'Donnell, Jr., M.D. ("O'Donnell") of Chesterfield, Missouri, are partners,
Williams, individually, O'Donnell individually, and STPI entered into a
Licensing Agreement on January 5, 1998 for certain intellectual property rights,
including without limitation Patent Rights under United States and foreign
patent applications relating to methods to cure tobacco so as to prevent
substantially the formation of tobacco-specific nitrosamines in cured tobacco,
and products containing such specially-cured tobacco, which license agreement
was amended on August 3, 1998 (hereinafter the "Basic License Agreement");

      1.3 WHEREAS as of March 16, 2001 STPI assigned all of its rights and
obligations under the Basic License Agreement to SSI and SSI assumed all such
rights and obligations;

      1.4 WHEREAS RCT and SSI terminated the Basic License Agreement and
superseded it with the Exclusive License Agreement effective as of March 16,
2001 (the "Exclusive License Agreement"); and

      1.5 WHEREAS, pursuant to and in accordance with Section 9 of the Exclusive
License Agreement, SSI desires to sublicense certain of its right under the
Exclusive License Agreement to STPI on the terms and conditions set forth
herein.
<PAGE>

      NOW, THEREFORE, the Parties enter into this License Agreement in
consideration of the mutual covenants and terms expressed herein.

2. PARTIES

      2.1 Star Scientific, Inc. ("SSI") is a Delaware corporation having its
principal place of business at 801 Liberty Way, Chester, Virginia 23836-2704.

      2.2 Star Tobacco & Pharmaceuticals, Inc. ("STPI") is a Virginia
corporation having its principal place of business at 801 Liberty Way, Chester,
Virginia 23836-2704.

3. DEFINITIONS

      3.1 "Patent Rights," as used in this Agreements, shall mean (i) all
claims of patent applications and issued patents which are now owned by SSI or
RCT in the United States and in foreign countries, or to which RCT has rights,
and which read on Low TSNA Tobacco or which read on the Know-How; (ii) all
claims of such patent applications and issued patents which may hereafter be
filed or issued, or of which SSI or RCT or Williams or O'Donnell may hereafter
become owner, or to which any of them may hereafter acquire rights during the
term of this Agreement, and which read on or relate to Low TSNA Tobacco or which
read on or relate to the Know-How; (iii) any inventions, conceived or reduced to
practice before the date of this Agreement or during the term of this Agreement,
and thereafter made the subject of a patent application, relating to the
production, treatment or curing of tobacco, or a method of manufacturing a
product containing tobacco, or of extracting one or more substances from tobacco
for the purpose of incorporating such substance or substances in a product or
products, and which SSI, RCT, Williams or O'Donnell may hereafter own or acquire
rights to. "Patent Rights" shall include, without limitation, U.S. Patents
5,803,081, 5,845,647, 6,135,121, 6,202,649, and any and all divisions,
continuations, continuations-in part, and reissues thereof.

      3.2 "Know-How," as used in this Agreement shall mean all information,
including without limitation trade secrets, whether or not patentable, relating
to, used in, or useful in connection with, Low TSNA Tobacco, or any methods or
devices which are claimed to result in
<PAGE>

and be useful in connection with tobacco or any product containing tobacco that
is less toxic and potentially less harmful to humans, or for which therapeutic
claims are made, whether any such information is now in the possession of RCT,
Williams or O'Donnell, or developed or acquired by any of them during the term
of this Agreement.

      3.3 "Low TSNA Tobacco" shall mean tobacco in which the formation of one or
more tobacco-specific nitrosamines has been substantially prevented during the
tobacco curing process. "Low TSNA Tobacco" shall also refer to any process or
device used to produce Low TSNA Tobacco.

      3.4 "Product" shall mean any article, composition, apparatus, substance,
chemical, material, method or services which is made, used, distributed or sold
which: (i) is covered in whole or in part by one or more pending or unexpired
claims contained in any patent included in the Patent Rights; (ii) is
manufactured using a method or process which is covered in whole or in part by
one or more pending or unexpired claims contained in any patent included in the
Patent Rights and/or which utilizes any of the Know-How; or (iii) the use of
which is covered in whole or in part by one or more pending or unexpired claims
contained in any patent included in the Patent Rights. For purposes of this
definition, a Product is covered by a pending or unexpired claim of a patent if
in the course of manufacture, use, distribution or sale, it would, in the
absence of this Agreement, infringe one or more claims of a patent which has not
been held invalid by a court from which no appeal can be taken.

      3.5 "License" shall mean the license granted in Section 4 hereof.

      3.6 "FDA" shall mean the United States Food and Drug Administration.

      3.7 "Licensor Affiliate" shall mean any entity controlled by Williams
and/or O'Donnell.

      3.8 "Royalties" shall mean the royalties payable by STPI to SSI as set
forth in Section 5.1 of this Agreement.
<PAGE>

      3.9 "Net Sales Price" shall mean the gross sales price of a Product, less
any rebates actually paid, discounts and allowances actually taken, and returns
to the extent credit is given or paid. There shall be no deduction from Net
Sales Price of any federal excise or sales taxes payable on account of the sale
of Products or otherwise, including without limitation tobacco product excise
taxes.

4. GRANT OF LICENSE

      4.1 Subject to the terms and conditions of this Agreement, SSI hereby
grants to STPI a non-transferable, non-exclusive and irrevocable license, with
no right to grant sublicenses, under the Patent Rights and under the Know-How to
make, have made, use, sell or otherwise dispose of, or deal in, any Product
anywhere in the world.

      4.2 STPI shall be jointly and severally obligated and liable to RCT for
all of the obligations of SSI under the Exclusive License Agreement, a copy of
which is attached hereto as Exhibit A.

5. ROYALTIES

      5.1 In consideration of the grant of License hereunder, STPI agrees to pay
to SSI a royalty of two percent (2%) on the Net Sales Price on the sale of
Products, less any Deductions, by STPI. As used herein, "Deductions" shall refer
to all expenses accruable under generally accepted accounting practices for (i)
the cost of applying for, obtaining, maintaining, enforcing and defending any
Patents Rights, (ii) research and development costs related to any Product or
any potential Product, or any improvement thereto, or any technology which would
be encompassed within the definition of Patent Rights or Know-How. Only those
Deductions accruable from and after January 1, 1998, shall be deducted from the
Net Sales Price in order to determine the amount of Royalties earned for that
period.

      5.2 All Royalties shall be paid by STPI to SSI on a quarterly basis within
thirty (30) days after the end of each calendar quarter in which such Royalties
are accrued. Each such payment shall be accompanied by an accounting statement,
which shall include:
<PAGE>

      (i) the quantity and classification (e.g., tobacco, cigarettes, snuff,
chewing tobacco, or cigars) of Products sold;

      (ii) the aggregate Net Sales Price of each classification of Products sold
and the aggregate Net Sales Price of all Products sold;

      (iii) the amount and classification (i.e., whether patent related expense
or research and development expense) of Deductions, and the aggregate amount of
all Deductions; and

      (iv) the total of all Royalties payable to SSI.

      5.3 STPI shall keep proper books of account showing sales of Products.
SSI's designated auditing firm shall have access to the books and records of
STPI at all reasonable times to independently determine the amount of Royalties
payable hereunder, but for no other purpose. All information obtained by SSI and
its auditing firm shall be kept strictly confidential by SSI and its auditing
firm.

6. RETENTION OF RIGHTS

      6.1 Notwithstanding any other provisions herein, RCT, SSI and SSI's other
sublicensees will have the absolute, nontransferable right to use the technology
covered by the Patent Rights and Know-How and all improvements thereof, for
conducting research and for any other purposes permitted pursuant to the
Exclusive License Agreement or any other sublicense agreements.

7. PATENT PROSECUTION

      7.1 SSI, and not STPI, shall be responsible for prosecuting all United
States patent applications, and foreign patent applications in such foreign
jurisdictions as SSI chooses, included within the Patent Rights, and for taking
action at its discretion as shall perfect or effect its title to the Patent
Rights.
<PAGE>

8. PATENT INFRINGEMENT

      8.1 STPI shall promptly notify SSI of all claims, allegations and
notifications of infringement of third party patents. Except for the placing in
escrow of a portion of royalties as referred to hereinafter, SSI shall have no
obligation or liability in the event that legal action is brought against STPI
for patent infringement. Such obligation and liability shall be borne by STPI.
STPI may choose legal counsel and defend the patent infringement lawsuit. During
such lawsuit, STPI may place all Royalties in an interest-bearing escrow
account. The escrow account shall be established in a bank mutually acceptable
to both parties under escrow instructions insulating the funds from claims of
any creditor. Upon termination of the action, one-half (1/2) of any judgment
amount, reasonable attorneys' fees and costs, may be paid from this escrow
account. In addition, should the settlement of any such patent infringement
lawsuit involve payment of royalties by STPI to a third party for the continued
right to manufacture, use and sell a Product, then funds in the escrow account
and royalties payable to SSI maybe applied against up to one-half (1/2) of such
royalties to a third party. Any funds thereafter remaining in the escrow shall
be paid to SSI. The above shall constitute SSI's sole liability and
responsibility in the event of such action. During the patent infringement
litigation each Party shall keep the other Party informed in writing of
significant developments in the lawsuit.

9. PATENT MARKING

      9.1 STPI shall use reasonable efforts to place all appropriate patent and
other intellectual property notices, markings and indicia on product and
marketing literature for any Products as needed to protect the patent and other
intellectual property rights of SSI and right for damages for infringement
thereof.

10. TERMINATION

      10.1 STPI may terminate this Agreement at any time, for any reason, by
providing SSI not less than thirty (30) days prior written notice thereof.

      10.2 SSI may terminate this Agreement upon the occurrence of any of the
following:
<PAGE>

      (i) A default in the payment of Royalties when due and payable, or a
failure to submit to SSI when due a true and complete accounting statement
pursuant to Section 5.2 of this Agreement, which default or failure continues
for a period of at least thirty (30) days after SSI has given to STPI written
notice of such default or failure.

      (ii) A material breach of any other obligation of STPI under this
Agreement, which breach shall not have cured within sixty (60) days after SSI
has given to STPI written notice of such breach, in which notice SSI shall have
specified in reasonable detail the nature of such breach. For purposes of
determining materiality, and provided the nature of the breach may be measured
in monetary terms, a breach shall be deemed "material" if such breach results in
a loss of Royalties exceeding $l00,000.

11. REMEDIES

      11.1 STPI acknowledges and agrees that any violation of this Agreement by
STPI would result in irreparable harm to SSI. Accordingly, STPI consents and
agrees that, if STPI violates any of the provisions of this Agreement, SSI shall
be entitled, in addition to other remedies available to it, to an injunction to
be issued by any court of competent jurisdiction restraining STPI from
committing or continuing any violation of this Agreement, without the need for
posting any bond or any other undertaking.

12. NOTICES, REPORTS AND PAYMENTS

      12.1 Any notice, report or payment permitted or required under this
Agreement shall be in writing, and shall be sent or delivered to the receiving
party at the address set forth below or at such address as either Party may from
time to time designate in writing.

If SSI to: Star Scientific, Inc.             If to STPI: Star Tobacco &
           7475 Wisconsin Avenue                         Pharmaceuticals, Inc.
           Suite 850                                     801 Liberty Way
           Bethesda, Maryland 20814                      Chester, Virginia 23836
           c/o Paul L. Perito, Chairman,                 c/o Paul H. Lamb, III
           President and Chief Operating                 President
           Officer
<PAGE>

13. PARAGPAPH HEADINGS

      13.1 Paragraph headings are for the convenience of this Agreement only and
shall not add to or detract from any of the terms or provisions.

14. SEVERABILITY

      14.1 If any provision of this Agreement is held invalid under any law
applicable to the Parties, RCT, other sublicensees and/or assignees, that
provision shall be considered severable and its invalidity shall not affect the
remainder of this Agreement, which shall continue in full force and effect.

15. CONTROLLING LAW, JURISDICTION AND VENUE

      15.1 This Agreement shall be deemed to be executed and to be performed in
the Commonwealth of Virginia, and shall be construed in accordance with the laws
of the Commonwealth of Virginia as to all matters, including but not limited to
matters of validity, construction, effect and performance. In the event of any
controversy, claim or dispute between the Parties hereto arising out of or
relating to this Agreement, such controversy, claim or dispute may be tried
exclusively in the courts of the Commonwealth of Virginia or in the United
States Federal District Court located in, or closest to, Richmond, Virginia, as
either party may elect. Each of the Parties hereby waives any defense of lack of
in personam jurisdiction, improper venue and forum non conveniens, and agrees
that service of process of such court may be made upon each of them by personal
delivery or by mailing certified or registered mail, return receipt requested,
to the other Party at the address provided for in Section 12 hereof. Both
Parties hereby submit to the jurisdiction of the court so selected, to the
exclusion of any other courts which may have had jurisdiction apart from this
Section 15.
<PAGE>

16. TERM OF THE AGREEMENT

      16.1 Except as otherwise terminated pursuant to the other provisions of
this Agreement, this Agreement shall terminate upon expiration of the last to
expire of the Patent Rights.

17. NEGATION OF WARRANTIES

      17.1 Nothing in this Agreement shall be construed as:

      (i) a warranty or representation by RCT or SSI as to the validity or scope
of any of the Patent Rights; or

      (ii) a warranty or representation that any Products made, used, sold or
otherwise disposed of under any license granted in this Agreement is or will be
free from infringement of patents of third parties; or

      (iii) an obligation to bring or prosecute actions or suits against third
parties for infringement; or

      (iv) conferring the rights to use in advertising, publicity or otherwise
any trademark, trade name, or names or any contraction, abbreviation, simulation
or adoption thereof, of RCT or SSI; or

      (v) any obligation to furnish any know-how not provided.

      17.2 NEITHER OF RCT OR SSI MAKES ANY EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, nor does either of RCT or
SSI represent that the rights granted hereunder will result in Products that are
commercially successful.

      17.3 STPI further agrees that it will nor rely upon technical information
provided by SSI in developing and manufacturing any Products hereunder, but will
independently test, analyze and evaluate all Products prior to manufacture and
distribution of such Products.
<PAGE>

18. INDEMNITY

      18.1 STPI shall defend, indemnify and hold harmless RCT and SSI and each
of their partners, employees and agents, and their respective successors, heirs
and assigns (the "Indemnitees"), against all liabilities, demands, losses,
costs, and expenses (including, without limitation, attorneys' fees) incurred by
or imposed upon the Indemnitees or any one of them in connection with any
claims, suits, actions, demands or judgments arising out of any theory of
liability (including but not limited to, actions in the form of tort, warranty,
or strict liability) for death, personal injury, illness, or property damage
arising from STPI's use, sale, or other disposition of any Products, or exercise
of any of rights under the License.

      18.2 STPI agrees, at its own expense, to provide attorneys reasonably
acceptable to SSI and RCT to defend against any actions brought or filed against
any party indemnified hereunder with respect to the subject of indemnity
contained herein, whether or not such actions are rightfully brought.

19. NON-TRANSFEASIBLITY

      19.1 This Agreement shall not be transferable by STPI by any transaction,
including without limitation sale, merger, or other transfer of assets by STPI,
without the express written consent of SSI.

20. ATTORNEYS' FEES

      20.1 In any action on or concerning this Agreement, the prevailing Party
shall be awarded its reasonable attorneys' fees, costs and necessary
disbursements, to be paid by the non-prevailing Party.

                                      10
<PAGE>

      IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of
the date first above written.

                                    STAR SCIENTIFIC, INC.

                                    By: /s/ Paul L. Perito
                                        ----------------------------------------
                                        Paul L. Perito, Chairman, President and
                                        Chief Operating Officer

                                    STAR TOBACCO &
                                    PHARMACEUTICALS, INC.

                                    By:
                                        ----------------------------------------
                                        Paul H. Lamb, III
                                        President

                                       11
<PAGE>

      IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of
the date first above written.

                                    STAR SCIENTIFIC, INC.

                                    By:
                                        ----------------------------------------
                                        Paul L. Perito, Chairman, President and
                                        Chief Operating Officer

                                    STAR TOBACCO &
                                    PHARMACEUTICALS, INC.

                                    By: /s/ Paul H. Lamb, III
                                        ----------------------------------------
                                        Paul H. Lamb, III
                                        President

                                      12<PAGE>

                                                                    Exhibit 10.3

                              CONSENT TO ASSIGNMENT

      This Consent to Assignment is made as of March 16, 2001 by and among
Regent Court Technologies ("RCT"), a general partnership of which Jonnie R.
Williams ("Williams"), of Manakin-Sabot, Virgin; and Francis O'Donnell, Jr.,
M.D. ("O'Donnell"), of Chesterfield, Missouri, are partners, Williams,
individually, O'Donnell individually, Star Tobacco & Pharmaceuticals, Inc., a
Virginia corporation ("STPI"), Star Scientific, Inc., a Delaware corporation
("SSI"), and Brown and Williamson Tobacco Corporation, a Delaware corporation
("B&W").

      Reference as made to the Licensing Agreement dated January 5, 1998 for
certain intellectual property rights, including without limitation United States
and foreign patent applications relating to methods to cure tobacco so as to
substantially prevent the formation of one or more tobacco-specific
nitrosamines, and products containing such specially-cured tobacco, which
License Agreement was amended on August 3, 1998 ("the Basic License Agreement").
Unless otherwise defined herein, capitalized terms used but not defined herein
shall have the meaning given such terms in the Basic License Agreement.

      Reference also is made to the Regent/B&W License Agreement dated August
15, 2000 ("Regent/B&W Agreement"), in which B&W was granted certain conditional
rights under the Basic License Agreement.

      WHEREAS, pursuant to Section 2 of the Basic License Agreement, RCT granted
to STPI certain rights and licenses with respect to certain RCT Patent Rights
and Know-How.

      WHEREAS, pursuant to amendment No. 2 of the Regent/B&W Agreement, the
provisions of the Basic License Agreement may not be amended or modified without
the prior written consent of B&W.

      WHEREAS, STPI wishes to assign any and all of its rights under the Basic
License Agreement to SSI.

      NOW, THEREFORE, the parties hereto agree as follows:

                                       1
<PAGE>

      1. Each of RCT, O'Donnell, Williams, STPI, and B&W hereby accepts the
assignment by STPI to SSI of all of STPI's rights and obligations under the
Basic License Agreement.

      2. From and after the date of this Agreement, STPI shall relinquish its
rights and be released from its obligations under the Basic License Agreement.
It is understood, however, that STPI may be hereafter granted rights by SSI
under the Basic License Agreement as an Affiliated Sublicensee of SSI.

      3. Each of RCT, O'Donnell, Williams, STPI, and B&W agrees that STPI shall
have no further obligation or liability with respect to RCT, SSI or any third
party arising out of the Patent Rights and Know-How or otherwise in connection
with the Basic License Agreement.

      4. Each of RTC, SSI and STPI hereby affirms that notwithstanding the
assignment of license rights from STPI to SSI and the execution of a new license
between RCT and SSI there will be no effect on the rights granted to Brown &
Williamson Tobacco Corporation under the Regent Court/B&W License Agreement
dated August 15, 2000.

      5. RCT acknowledges receipt of a copy of the Restated Master Agreement
dated April 25, 2001 and the related agreements (as therein defined). RCT
acknowledges that it is a Star Affiliate as that term is defined in the Restated
Master Agreement, and agrees to be bound by all the terms and provisions of the
Restated Master Agreement and Related Agreements which are applicable to Star
Affiliates.

      IN WITNESS WHEREOF, the parties hereto have caused this Consent to
Assignment to be executed as of the date first above.

                                        REGENT COURT TECHNOLOGIES

                                    By: /s/ Francis E. O'Donnell
                                        --------------------------------------
                                        Francis E. O'Donnell, General Partner

                                    By: /s/ Francis E. O'Donnell, Jr.
                                        --------------------------------------
                                        FRANCIS E. O'DONNELL, JR.

                                       2
<PAGE>

                                        /s/ Jonnie R. Williams
                                        --------------------------------------
                                        JONNIE R. WILLIAMS

                                        STAR TOBACCO & PHARMACEUTICALS, INC.

                                    By: /s/ Paul H. Lamb, III
                                        --------------------------------------
                                        Paul H. Lamb, III, President

                                        STAR SCIENTIFIC, INC.

                                    By: /s/ Paul L. Perito
                                        --------------------------------------
                                        Paul L. Perito, Chairman, President
                                        and Chief Operating Officer

                                        BROWN AND WILLIAMSON TOBACCO
                                        CORPORATION

                                    By: /s/
                                        --------------------------------------
                                        Its Executive Vice President

                                       3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]